Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds virus or component thereof
Reexamination Certificate
1998-08-26
2002-04-16
Zeman, Mary K. (Department: 1631)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds virus or component thereof
C424S130100, C424S139100, C424S159100, C424S176100, C530S387100, C530S389100, C530S389400, C530S390100
Reexamination Certificate
active
06372216
ABSTRACT:
The present invention relates to a drug adapted to protect individuals against the viral hepatitis infection.
It was only in the early 40's, in the U.S.A., that viruses (designated. “hepatitis A and hepatitis B viruses”) capable of causing hepatitis were detected in samples of human blood. Individuals invariably recover from viral hepatitis A, whereas 5-10% of patients affected by viral hepatitis B do not recover, but go on to develop chronic hepatitis or become asymptomatic chronic carriers of the disease. The serum of patients who recover from viral hepatitis infection contains antibodies that neutralize the effect of the virus.
Consequently, in an attempt to protect individuals at-risk of contracting the infection, researchers began first to produce immune serum globulins and later vaccines.
When only hepatitis A and B viruses were known, all viral hepatitis infections not attributable to these viruses were called “nonA-nonB hepatitis”. It is important to note that the hepatitis C virus (HCV) was discovered only about seven years ago and that it is the cause of the majority (80%) of parenterally transmitted nonA-nonB hepatitis cases.
Hepatitis C infection can be very severe because of its fatal sequelae, i.e., chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Only about 20-30% of infected individuals recover from the disease. Furthermore, infected subjects can transmit the infection to other individuals by means of their blood, the sexual route, etc.
It should be noted that most HCV-infected individuals are asymptomatic. Therefore, they are often unaware they have the infection and can transmit it to others.
While vaccines and specific immune preparations are used for the prevention of hepatitis A and B infection, there are at present no measures to protect all the many subjects exposed to the risk of acquiring HCV infection.
At present, HCV affects about 300 million people worldwide. Given the lack of effective protective measures, these infected individuals are a potential danger because they can spread this scourge through the world with devastating human, social and economic consequences.
The drug according to the present invention intends to make available to mankind a product that can effectively protect from HCV infection and is characterized by a substantial hyperimmunity against HCV, said hyperimmunity being due to a substantial hyperconcentration of virus C neutralizing antibodies.
Furthermore the drug according to the invention would be produced from blood units collected from HCV-infected individuals that contain a substantially high concentrations of HCV neutralizing antibodies. The final product would be safe because any HCV or any other possible infectious agents, that could be present in the blood units used for preparing the drug according to the invention, are inactivated by the Cohn method (alcohol fractionation) and/or by other possible virucidal treatments and/or additional methods capable of inactivating infectious agents.
At last, the use of the drug according to the invention is directed to substantially protect the individuals against HCV infection, such as, for example:
sexual partners of HCV-infected patients,
patients undergoing hemodialysis,
patients undergoing dental therapy or chiropodistry,
drug abusers,
patients affected by HCV-related fulminate hepatitis, liver cirrhosis or hepatocellular carcinoma undergoing liver transplantation,
etc, etc.
Additionally, the use of the drug according to the invention is also directed to substantially block HCV infection in all other possible conditions.
These and further features of the drug according to the invention will be apparent from the following description.
REFERENCES:
patent: 5670312 (1997-09-01), Santi
patent: 5972347 (1999-10-01), Eder et al.
Farci et al. 1996 PNAS USA vol. 93 pp. 15394-15399 Dec. 1996.*
Farci et al.,“Hepatitis C virus: genetic heterogeneity and immunity”, Trends in Experimental Clinical Medicine vol. 6 pp. 177-185 (1996).*
Bukh et al., “Genetic Hererogeneity of Hepatitis C Virus: Quasispecies and Genotypes”, Seminars In Liver Disease vol. 15 No. 1 (1995) pp. 41-63.*
Piazza et al. Sexual Transmission of Hepatitis C Virus and Prevention with Intramuscular Immunoglobulin. 1998, AIDS Patient Care and STD's, vol. 12 No. 8 pp. 611-618.*
Who Technical Report Series, No. 840, pp. 34 to 99, “Requirements For The Collection, Processing And Quality Control Of Blood, Blood Components And Plasma Derivatives”, 1994 (with remarks on the EPO International Preliminary Examination Report).
Krzysztof Krawczynski, et al., The Journal of Infectious Diseases, vol. 173, pp. 822 and 828, “Effect Of Immune Globulin On The Prevention Of Experimental Hepatitis C Virus Infection”, 1996 (with AASLD Abstracts).
M. W. Yu, et al., International Meeting on Hepatitis C Virus and Related Viruses Molecular Virology and Pathogenesis, abs H13, p. 223, “Presence Of Protective Antibodies In An Experimental Intravenous Immune Globulin Prepared From Anti-HCV Positive Donor Units”, Jun. 25—28, 1998.
K. Krawczynski, et al., Abstracts of 49th Annual Meeting AASLD, abs 398A and 944, “Early Termination Of HCV Infection By Passive Anti-HCV Transfer In Experimentally Infected Chimpanzees”, Nov. 6 to 10, 1998.
Alfred M. Prince et al., “Sterilisation of Hepatitis and HTLV-III Viruses by Exposure to TRI(n-butyl)Phosphate and Sodium Cholate”,The Lancet, Mar. 29, 1996, vol. 1, pp. 706-710.
Freja Ebeling, et al., “Tolerability and Kinetics to a Solvent-Detergent-Treated Intravenous Immunoglobulin Preparation in Hypogamma-Globulinaemia Patients,”Vox Sang, 1995, vol. 69, pp. 91-94.
M.P.J. Piet et al., “The Use of Tri(n-butyl)phosphate Detergent Mixtures to Inactive Hepatitis Viruses and Human Immunodeficiency Virus in Plasma and Plasma's Subsequent Fractionation,”Transfusion, vol. 30, No. 7, 1990, pp. 591-598.
Robert E. Louie et al, “Inactivation of Hepatitis C Virus in Low pH Intravenous Immunoglobulin,”Biologicals, vol. 22, 13-19, 1994.
Richard I. Schiff, M.D., Ph.D., “Transmission of Viral Infections Through Intravenous Immune Globulin,”The New England Journal of Medicine, vol. 331, No. 24, pp. 1649-1650, Dec. 15, 1994.
K. G. Reid, et al., “Potential Contribution of Mild Pepsin Treatment at pH4 to the Viral Safety of Human Immunoglobulin Products,”Vox Sang, vol. 55, pp. 75-80, 1988.
Thomas Nowak, et al., “Virus Safety of Human Immunoglobulins: Efficient Inactivation of Hepatitis C and Other Human Pathogenic Viruses by the Manufacturing Procedure,”Journal of Medical Virology, vol. 36, pp. 209-216, 1992.
J. L. Oncley, et al., “The Separation of the Antibodies, Isoagglutinins, Prothrombin, Plasminogen and &bgr;1-Lipoprotein into Subfractions of Human Plasma,”J. Am. Chem. Soc., 1949, vol. 71, pp. 541-550.
E. J. Cohn, et al., “Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids,”J. Am. Chem. Soc., vol. 68, 1946, pp. 459-475.
D. Y. Chien et al., “Persistence Of HCV Despite Antibodies To Both Putative Envelope Glycoproteins”,The Lancet, Oct. 9, 1993, vol. 342, p. 933.
K. Krawczynski et al., “Studies On Protective Efficacy Of Hepatitis C Immunoglobulin (NGIO) In Experimental Hepatitis C Virus Infection”,Hepatology, American Association for the Study of Liver Diseases Abstracts, Oct. 1994, No. 214, p. 110A.
Marcello Piazza et al., “Sexual Transmission Of The Hepatitis C Virus And Efficacy Of Prophylaxis With Intramuscular Immune Serum Globulin”,Archives of Internal Medicine, Original Investigation, Jul. 28, 1997, vol. 157, No. 14. pp. 1537-1544.
Q.-L. Choo et al., “Vaccination Of Chimpanzees Against Infection By The Hepatitis C Virus”,Proc. Natl. Acad. Sci. USA, Medical Sciences, Feb. 1994, vol. 91, pp. 1294-1298.
Domenico Rosa et al., “A Quantitative Test To Estimate Neutralizing Antibodies To The Hepatitis C Virus: Cytofluorimetric Assessment Of Envelope Glycoprotein 2 Binding To Target Cells”,Proc. Natl. Acad. Sci. USA, Biochemistry, Mar. 1996, vol. 93, pp. 1759-1763.
Koji Ishi
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Zeman Mary K.
LandOfFree
Method of producing specific immunoglobin to block HCV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of producing specific immunoglobin to block HCV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of producing specific immunoglobin to block HCV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2842097